Viatris saw the highest growth of 3.99% in patent filings and 1.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.19% and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Viatris‘s patent filings and grants. Buy the databook here.
Viatris has been focused on protecting inventions in United States(US) with four publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 43% filings and 25% grants. The United States(US), World Intellectual Property Organization(WIPO), European Patent Office(EPO), and Australia(AU) patent Office are among the top ten patent offices where Viatris is filings its patents. Among the top granted patent authorities, Viatris has 50% of its grants in European Patent Office(EPO), 25% in United States(US) and 25% in Spain(ES).
Roche could be the strongest competitor for Viatris
Patents related to health & wellness and meat & seafood alternatives lead Viatris's portfolio
Viatris has the highest number of patents in health & wellness followed by, meat & seafood alternatives and remote patient monitoring. For health & wellness, nearly 17% of patents were filed and no patents were granted in Q2 2024.
Keratoconjunctivitis sicca (dry eye) related patents lead Viatris portfolio followed by drug delivery devices, and pain
Viatris has highest number of patents in keratoconjunctivitis sicca (dry eye) followed by drug delivery devices, pain, emesis (vomiting), and caries. For keratoconjunctivitis sicca (dry eye), nearly 12% of patents were filed and 67% of patents were granted in Q2 2024.
For comprehensive analysis of Viatris's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.